At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
The company will also share results in two additional posters for deuruxolitinib
Global survey reveals top workforce concerns, evolving strategic priorities, and key technology investment areas for life sciences manufacturers
Pfizer's decision is based on the totality of clinical data
She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma
Subscribe To Our Newsletter & Stay Updated
